Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
8509302897!OTHER MEDICAL is a federal award for Dla Troop Support held by Pfizer Inc. Estimated value $871K ($819K obligated). Current period of performance ends Aug 31, 2023. Place of performance: NEW YORK NY.
Recompete timing
PublicCurrent PoP ended Aug 31, 2023 (1086 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordPfizer Inc — $3.2B obligated across 1,961 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2D022F0338?
SPE2D022F0338 (8509302897!other medical) is a Dla Troop Support award with a potential value of $871K, currently held by Pfizer Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is SPE2D0-22-F-0338?
SPE2D0-22-F-0338 is the dashed form of PIID SPE2D022F0338 (8509302897!other medical), held by Pfizer Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded SPE2D022F0338?
Dla Troop Support awarded SPE2D022F0338 to Pfizer Inc (potential $871K).
Who is the incumbent on SPE2D022F0338?
Pfizer Inc is the incumbent with $3.2B across 1961 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2023.
When does Pfizer Inc’s SPE2D022F0338 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.
